Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887698 | 0.82 | AKR1B1 (0.53) | AKR1B1SRCPTGS2MAPTALOX15 | |
| SCHEMBL4887267 | 0.80 | AKR1B1 (0.55) | AKR1B1SRCPTGS2MAPTSMN1; SMN2 | |
| SCHEMBL14363376 | 0.79 | TRPA1 (0.50) | MAPTALOX15SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL27745589 | 0.76 | SRC (0.56) | AKR1B1SRCPTGS2MAPTALOX15 | |
| SCHEMBL3228305 | 0.73 | SRC (0.62) | AKR1B1SRCPTGS2MAPTALOX15 | |
| SCHEMBL29481933 | 0.73 | SRC (0.62) | AKR1B1SRCPTGS2MAPTALOX15 | |
| SCHEMBL27625189 | 0.73 | AKR1B1 (0.68) | AKR1B1PTGS2MAPTKDM4EMEN1 | |
| SCHEMBL3907285 | 0.72 | AKR1B1 (0.67) | AKR1B1PTGS2MAPTKDM4EMEN1 | |
| SCHEMBL4619074 | 0.71 | AKR1B1 (0.41) | AKR1B1ALDH1A1PTGS1 | |
| SCHEMBL9890649 | 0.70 | PTGS1 (0.59) | AKR1B1SRCPTGS2MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319043-A1 | 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM5, CHRM2 | AKR1B1 513/4885SRC 2345/4885PTGS2 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.